Literature DB >> 16480927

TNF alpha production to TLR2 ligands in active IBD patients.

Elisabet Cantó1, Elena Ricart, David Monfort, Dolors González-Juan, Joaquim Balanzó, José L Rodríguez-Sánchez, Sílvia Vidal.   

Abstract

Strong evidence suggests that microbial components are involved in the etiopathology of inflammatory bowel diseases (IBD). Since pathogen-associated molecular patterns are recognized by TLRs, dysregulation of TLR-mediated microbial recognition could be taking place in IBD patients. An in vitro assay with different TLR agonists was used to reproduce the immunostimulation via TLR ligands. Elevated TNFalpha production was found in response to LTA and Zymosan in 48% of active Crohn's disease and ulcerative colitis patients when compared to inactive patients or controls. The expression of CD14 did not differ in active patients, whereas TLR2 was significantly upregulated on monocytes from 71% of those patients with high production of TNFalpha. The marked increase of TNFalpha response to TLR2 ligands correlated with a higher TLR2 expression in a group of IBD patients, suggesting that an abnormal mechanism may provide an excess of inflammatory mediators during the active phase of IBDs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16480927     DOI: 10.1016/j.clim.2005.12.005

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  25 in total

Review 1.  Cardiovascular complications in inflammatory bowel disease.

Authors:  Rudolf Schicho; Gunther Marsche; Martin Storr
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

Review 2.  Toll-like receptors in inflammatory bowel disease-stepping into uncharted territory.

Authors:  Avi Levin; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

3.  Structural basis for solute transport, nucleotide regulation, and immunological recognition of Neisseria meningitidis PorB.

Authors:  Mikio Tanabe; Crina M Nimigean; T M Iverson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

Review 4.  The critical role of macrophages in the pathogenesis of hidradenitis suppurativa.

Authors:  Ahmed Shah; Raed Alhusayen; Saeid Amini-Nik
Journal:  Inflamm Res       Date:  2017-06-27       Impact factor: 4.575

5.  Time-course of Toll-like receptor 2 expression, as a predictor of recurrence in patients with bacterial infectious diseases.

Authors:  K Orihara; K Nagata; S Hamasaki; R Oba; H Hirai; S Ishida; T Kataoka; N Oketani; M Ogawa; E Mizoguchi; H Ichiki; C Tei
Journal:  Clin Exp Immunol       Date:  2007-05       Impact factor: 4.330

6.  Immune phenotype in children with therapy-naïve remitted and relapsed Crohn's disease.

Authors:  Aron Cseh; Barna Vasarhelyi; Kriszta Molnar; Balazs Szalay; Peter Svec; Andras Treszl; Antal Dezsofi; Peter-Laszlo Lakatos; Andras Arato; Tivadar Tulassay; Gabor Veres
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

7.  Differential expression of TLR2, TLR4 and JNK in mucosa of ileal pouches for ulcerative colitis. Is there a role for bacterial antigen pathway in asymptomatic patients?

Authors:  Nielce M de Paiva; Maria L S Ayrizono; Marciane Milanski; Andressa Coope; Luiza M F Oliveira; João J Fagundes; Lício A Velloso; Cláudio S R Coy; Raquel F Leal
Journal:  Int J Clin Exp Med       Date:  2011-09-15

8.  Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease.

Authors:  B Szebeni; G Veres; A Dezsõfi; K Rusai; A Vannay; M Mraz; E Majorova; A Arató
Journal:  Clin Exp Immunol       Date:  2007-11-07       Impact factor: 4.330

Review 9.  The potential of targeting Toll-like receptor 2 in autoimmune and inflammatory diseases.

Authors:  E M Pålsson-McDermott; L A J O'Neill
Journal:  Ir J Med Sci       Date:  2007-11-15       Impact factor: 1.568

Review 10.  The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease.

Authors:  Megan E Himmel; Gijs Hardenberg; Ciriaco A Piccirillo; Theodore S Steiner; Megan K Levings
Journal:  Immunology       Date:  2008-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.